Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/24/20
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 09/30/16
End: 02/28/19
Due: 02/28/20
Phase: N/A
Priority: Normal
Start: 09/30/16
End: 11/23/20
Due: 11/23/21
Phase: N/A
Priority: Normal
Start: 01/11/19
End: 11/17/21
Due: 11/17/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Zhejiang DTRM Biopharma | user2@example.com | None | 2020-04-24 | 2024-12-31 | 2025-12-31 | - | - | 2025-07-14 |
| Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas | NCT02891590 | Zhejiang DTRM Biopharma | user2@example.com | None | 2016-09-30 | 2019-02-28 | 2020-02-28 | - | - | 2025-07-14 |
| Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas | NCT02900716 | Zhejiang DTRM Biopharma | user2@example.com | None | 2016-09-30 | 2020-11-23 | 2021-11-23 | - | - | 2025-07-14 |
| BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma | NCT03836768 | Zhejiang DTRM Biopharma | user2@example.com | None | 2019-01-11 | 2021-11-17 | 2022-11-17 | - | - | 2025-07-14 |